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Volume 58, Number 2 Abstracts 561restored. Medical therapy will continue as long as there is observed clinical
beneﬁt. There were no apparent adverse side effects of sirolimus therapy.
Conclusions: While vascular malformations must be managed on an
individual basis, this case presents a potentially promising method to treat
those with severe complications. A staged surgical and medical approach
restored normal limb function and resolved critical consumptive coagulop-
athy in an infant. The optimal choice for medical therapy requires further
study, but sirolimus appears to be a promising option.Fig.Potential Association of a Single Nucleotide Polymorphism in the
CDNK1B Gene and Carotid Plaque Fibrous Cap Status by MRI
Thomas S. Hatsukami, MD, Gail P. Jarvik, MD, PhD, Daniel S. Hippe, M.S,
Jane E. Ranchalis, Alexander W. Clowes, MD. Surgery, University of
Washington, Seattle, Wash
Objectives: Studies have shown that individuals with a thin or
ruptured ﬁbrous cap on carotid magnetic resonance imaging (MRI) are at
greater risk for transient ischemic attack or stroke. Autopsy studies docu-
ment a similar relationship between cap rupture and myocardial infarction
(MI). Recent evidence suggests that a single nucleotide polymorphism in
the promoter region of the CDKN1B gene, a cell cycle regulator, is associ-
ated with a two-fold increased risk of MI. These studies indicate that the
-838A allele is associated with increased CDKN1B expression and decreased
proliferation of vascular smooth muscle cells (SMC). Reduction in SMC
proliferation may result in decrease in the thickness of the ﬁbrous cap,
setting the stage for cap rupture. The objective of this study is to test that
hypothesis that the -838A allele of the CDKN1B gene is associated with
the presence of a thin or ruptured ﬁbrous cap on carotid MRI.
Methods: 276 subjects with 16-79% carotid stenosis by ultrasound
were recruited for the study. Carotid MRI scans were performed on a 1.5 T
scanner (Signa Horizon EchoSpeed, GE Healthcare, Milwaukee, WI). The
index artery was analyzed by reviewers blinded to clinical and genetic informa-
tion. Carotid plaque composition and ﬁbrous cap status were recorded using
previously published criteria. The trend between number of A alleles and the
presence of a thin or ruptured ﬁbrous capwas assessed using logistic regression
under a codominant genetic model.
Results: Of the 276 carotid arteries, 42 (15%) were excluded due to
insufﬁcient image quality and 60 subjects did not agree to sample collection
for genotyping, leaving a total of 174 arteries for analysis. Sixty-one (35%) of
the plaques had a thin or ruptured cap. The Fig summarizes the prevalence
of thin/ruptured ﬁbrous cap by genotype. There was a trend toward
increasing prevalence of thin/ruptured caps with each A allele, but this
was of marginal statistical signiﬁcance (P ¼ .062) in this small sample.Fig.Conclusions: These preliminary data suggest a trend toward increasing
prevalence of thin/ruptured caps in carotid plaque associated with the
-838C>A polymorphism of the CDKN1B gene that warrants further study
in a larger cohort. Furthermore, this study demonstrates the utility of MRI
for examining the pathogenesis of the high-risk atherosclerotic plaque.
Leveraging the Electronic Medical Record to Implement an Abdominal
Aortic Aneurysm Screening Program in a Large Integrated Health
Care System
Robert J. Hye, MD,1 Andrea Smith, RN,2 Gary H. Wong, MD, MPH,2
Southida Vansomphone, Pharm. D,2 Ronald D. Scott, MD,3 Michael H.
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Objectives: Screening for Abdominal Aortic Aneurysm (AAA)
reduces aneurysm related mortality. US Preventive Services Task Force
(USPTF) and American Heart Association (AHA) have recommended
screening in high risk groups since 2005. Since 2007, Medicare has covered
a one-time screening ultrasound for new male enrollees with a familial or
smoking history. Nevertheless, in the United States, screening has remained
underutilized. Review of patients with ruptured AAA in our system in 2009
showed the vast majority were undiagnosed yet met USPTF and AHA
screening guidelines. To reduce the number of preventable AAA ruptures
and deaths in our health plan members, we implemented an AAA screening
program using our electronic medical record (EMR). This study describes
the design, implementation and early results of that screening program.
Methods: Men aged 65-75 with any history of smoking were targeted
for screening. Medical records were reviewed electronically to exclude
patients with known aneurysms, repaired aneurysms and individuals with
an abdominal imaging study within 10 years that would have diagnosed
an AAA. Best Practice Alerts (BPA) were created in the EMR so when an
appropriate patient is seen, ofﬁce staff and providers are prompted to order
an abdominal ultrasound. AAA was deﬁned as aortic diameter 3 cm or
greater and ultrasound reports contained a standard template providing
guidance for management when an aneurysm was identiﬁed. Newly identi-
ﬁed AAA were triaged for Vascular Surgery consultation or follow-up. The
number of screening exams and AAA identiﬁed were tabulated by our
Screening and Safety Net Program.
Results: In a population of 3.6 Million, 64,848 patients met
screening criteria and 54.7% were excluded from the BPA. In the ﬁrst 8
months after starting the BPA, 12,614 abdominal ultrasound or CT scans
were performed and 1335 new AAA diagnosed. Screening rates have
increased at all medical centers and the percentage of unscreened patients
has been reduced from 45.3% to 25.9% system wide.
Conclusion: In an integrated Health Care System using an EMR,
AAA screening can be implemented with a dramatic increase in screening
exams and yield of previously undiagnosed AAA. Further analysis is required
to assess the impact of the screening program on AAA rupture rate and cost-
effectiveness in our system.Fig.Fate and Follow-up of Patients with Small and Intermediate Diameter
Abdominal Aortic Aneurysms in a Screening Program
LeAnn A. Chavez, MD,1,2 Kevin C. Chun, BS,2 Kai Y. Teng, BS,2 Kiana
M. Samadzadeh, BS,2 Eugene S. Lee, MD, PhD1,2. 1University of
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Sacramento, Calif
Objectives: An AAA screening program implemented in 2007,
remains active today. During screening, many patients with aortic diameters
Table.
Aortic diameter
size, cm N = 227
Screening
AAA size, cm
Follow-up
AAA size, cm
Average
follow-up, years
Percent follow-up
>6 months
Expansion
rate, cm/yr
3.0-3.9 157 3.4 3.7 2.1 157/362 (43.4%) 0.16
4.0-5.4 70 4.5 4.9 1.8 70/113 (61.9%) 0.22
P value - - - - 0.04 0.71
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562 Abstracts August 2013of 3.0-5.4 cm were identiﬁed. The purpose of our study is to investigate the
fate of patients diagnosed with an aorta too small for repair.
Methods: Data were extracted through a regional Veterans Affairs
Service Network to identify all veteran males 65-75 years of age who
smoked greater than 100 cigarettes during their lifetime. Patients meeting
screening criteria were evaluated for an AAA as part of the patient's health
maintenance. An aortic diameter of 3.0 cm to 3.9 cm was considered to be
a SMALL AAA, whereas INTERMEDIATE AAA was an aortic diameter
4.0-5.4 cm. Follow-up rates, rate of aortic expansion, and risk factors for
expansion were evaluated. Chi squared analysis and two-tailed t-test were
used to compare groups. A P-value < .05 was considered signiﬁcant.
Results: A total of 9,751 patients (71.5 6 5.6 SD years of age) were
screened for an AAA over a 5 year period from January 1, 2007 to
December 31, 2011. A total of 698 patients were identiﬁed with an aneu-
rysm (7.1%). Five-hundred-nineteen patients had an aortic diameter of
3.0-5.4 cm upon initial screening; 13 aneurysms were repaired and 31
had follow-up imaging less than 6 months after initial screening. During
study period, 47.8% (227/475) patients had a follow-up image study
completed more than 6 months after initial screening. The average expan-
sion rate for SMALL AAA was 0.16 cm/year versus INTERMEDIATE
AAA with 0.22 cm/year (P < .71). No signiﬁcant differences were found
in risk factors between groups.
Conclusions: The long-term implementation of an AAA screening
effort has led to the diagnosis of a signiﬁcant number of patients with small
and intermediate diameter aortas with lacking data-driven recommendations
for long term follow-up. Our data suggest that follow-up among patients
with small to intermediate sized aneurysm are substantially low. Expansion
rates are variable and risk for expansion need to be further elucidated.Endoleaks Following EVAR: Long-Term Outcome and Clinical
Signiﬁcance
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Objectives: EVAR is considered the standard therapy for most
patients with AAA. Endoleak is a well-known EVAR-related complication
that requires long-term follow-up. However, patient follow-up is often chal-
lenging outside clinical trials. We sought to evaluate the incidence and the
effect of endoleaks in a VA health care system where long-term follow-up is
ensured.
Methods: We retrospectively evaluated 213 consecutive patients who
received EVARs at a referral VA medical center. Age, aneurysm size, patency
of lumbar and IMA, and follow-up evaluations were recorded. Type of
endoleak, date of detection and intervention were also documented.
Patients who had less than 1-year follow-up were excluded. Student’s
t-test and spearman correlation were used for data analysis.
Results: A total of 180 patients were included in the analysis with
a mean follow-up of 51 months. Thirty-ﬁve were excluded due to death
within 1 year of EVAR (n ¼ 14), lost to follow-up (n ¼ 5), or too early
for 1 year CT (n ¼ 14). Fifty-two (28.9%) patients had endoleaks. The
mean diagnosis time for type I (n¼12) and type III (n ¼ 4) endoleaks
was 46 and 21 months post-EVAR and the majority (62.5%) were diag-
nosed >1 year following EVAR. All type I and III endoleaks received
secondary interventions except one who presented with aneurysm rupture.
Type II endoleak was detected in 37 patients on an average of 14 months
following EVAR and 39.4% of which were detected >1 year post EVAR.
Patients without documented endoleak had signiﬁcant decrease in aneurysm
size compared to the preoperative size (4.78 vs 5.65 cm; P < .001), while
those with type II endoleak had increase compared to the preop (5.82 vs
5.66 cm). Importantly, 51.4% of the patients with a type II endoleak had
signiﬁcant AAA enlargement (0.75 cm). No signiﬁcant correlation between
the size of IMA or lumbar to AAA enlargement among the patients with
a type II endoleak was seen. 9 patients with type II endoleak received
secondary interventions.Conclusions: We demonstrated that endoleak often appears long
after EVAR despite the normal initial imaging and that type II endoleak
is frequently associated with long-term aneurysm enlargement requiring
reinterventions. This study underscores that type II endoleak is not benign
as previously thought and that vigilant long-term surveillance following
EVAR is critical.
No Difference in Mortality After Inter-Facility Transfer for Patients
with Ruptured Abdominal Aortic Aneurysm
Matthew W. Mell, MD, MS, N. Ewen Wang, MD, Doug E. Morrison, MS,
Tina Hernandez-Boussard, PhD, MPH. Surgery, Stanford University,
Stanford, Calif
Objectives: Patients receiving inter-facility transfer to a higher level of
medical care for ruptured abdominal aortic aneurysms (rAAA) are an impor-
tant minority that are not well characterized and typically omitted from
outcomes and quality indicator studies. Our objective was to compare
patients transferred for treatment of rAAA with those treated without trans-
fer, with particular emphasis on quality of care.
Methods: We linked longitudinal data from 2005-2010 HCUP State
Inpatient Databases and Emergency Department Databases from Califor-
nia, Florida, and New York. Patients were identiﬁed using ICD-9-CM
codes. Our main outcome variables were mortality, length of stay (LOS),
and cost. Data included discharge information on both the transfer-out
and transfer-in hospital. We used univariate and multivariate analysis to
identify variables independently associated with transfer and in-hospital
mortality.
Results: Of 4413 rAAA patients identiﬁed with intent to treat, 819
(18.6%) were transferred prior to receiving deﬁnitive care. Of those trans-
ferred, 134 (16%) died without undergoing AAA repair. Risk-adjusted in-
hospital mortality did not differ by transfer status (45.7% vs 43.1%; P ¼ .2),
but LOS (median, 10 vs 9 days; P ¼ .008), and hospital costs ($158,000 vs
$146,000; P ¼ .04) were higher for those transferred. By multivariate anal-
ysis, age (OR, 0.98; 95% CI, 0.97-0.99; P< .001) private insurance vs Medi-
care (OR, 0.59; 95% CI, 0.46 - 0.77; P< .001), and comorbidity (OR, 0.93;
95% CI, 0.89-0.97; P ¼ .003) were negatively associated with transfer.
Weekend presentation (OR, 1.28; 95% CI, 1.08-1.52; P ¼ .005) was posi-
tively associated with transfer.
Conclusions: Mortality was similar for patients transferred for rAAA
repair compared with those not transferred, although 16% of transferred
patients died without receiving deﬁnitive repair. Transferred patients used
signiﬁcantly more hospital resources. Improving systems and guidelines
for inter-facility transfer may improve the quality of care received by these
patients and decrease associated hospital resource utilization.
Early and Late Outcomes Following Abdominal Aortic Aneurysm
Repair Requiring a Suprarenal Cross-Clamp
Sarah M. Wartman, MD Karen Woo, MD Andrew Yaeger, BS S Grace
Huang, MD Vincent Rowe, MD Fred A. Weaver, MD. University of
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Objectives: To analyze the early and late outcomes of patients who
require a suprarenal aortic cross-clamp during elective open repair of an
abdominal aortic aneurysm (AAA).
Methods: Patients from 1998-2011 who required a suprarenal aortic
cross-clamp during elective open AAA repair were reviewed. Data abstracted
included: demographics, comorbidities, preoperative, perioperative, and late
renal function; late interventions related to AAA repair; and late mortality. A
decrease in renal function was deﬁned as a >30% decline in eGFR as
compared to the preoperative value. Primary outcomes included renal func-
tion, intervention free survival and overall survival.
Results: One hundred eighty-six patients underwent open AAA
repair; 63 of whom required a suprarenal cross-clamp. Mean age was 72
with 81% being male. Mean preoperative creatinine was 1.2 mg/dL and
mean preoperative eGFR was 65 mL/min/1.73m2. Location of the aortic
cross-clamp was suprarenal (36), supramesenteric (18), and supraceliac (9).
Perioperatively, 15 (24%) patients experienced a signiﬁcant decrease in
